We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

AGILENT

Agilent provides laboratories worldwide with instruments, services, consumables, applications and expertise, enabling... read more Featured Products: More products

Download Mobile App




Novel Microfilarial Antigen Diagnoses Lymphatic Filariasis Infections

By LabMedica International staff writers
Posted on 08 Jun 2022

Lymphatic filariasis is a neglected tropical disease caused by the filarial nematodes Wuchereria bancrofti, Brugia malayi and Brugia timori. More...

Lymphatic filariasis (LF) is a deforming and disabling disease caused by parasitic nematodes that are transmitted by mosquitoes.

Antibodies to some filarial antigens become detectable in blood sooner after exposure or infection, than microfilaria (Mf) or circulating filarial antigen (CFA). Furthermore, antibody assays may be more sensitive than tests for CFA or Mf for detecting filarial infections or exposure to infection in children.

Infectious Disease Specialists at the Washington University School of Medicine (St Louis, MO, USA) report the discovery and characterization of a novel W. bancrofti antigen, Wb-Bhp-1, which is a homologue of the Brugia malayi protein used in antibody tests to monitor filariasis elimination in areas of Asia where LF is caused by Brugia species. The team used various techniques to study the antigen diagnostic potential, including cloning and expression, tissue fixation and immunohistochemistry, immunoblot analysis, and indirect ELISA. They tested sera or plasma from patients infected with W. bancrofti, B. malayi, Onchocerca volvulus and Loa loa. Slides were examined on an Olympus -BX40 microscope and photographed on an Olympus DP70 microscope digital camera (Olympus, Tokyo Japan).

The scientists reported that immunohistology showed that anti-Wb-Bhp-1 antibodies primarily bind to Mf. Plasma from 124 of 224 (55%) microfilaremic individuals had IgG4 antibodies to Wb-Bhp-1 by ELISA. Serologic reactivity to Wb-Bhp-1 varied widely with samples from different regions (sensitivity range 32%–92%), with 77% sensitivity for 116 samples collected from microfilaremic individuals outside of sub-Saharan Africa. The team screened sera from people infected with W. bancrofti, and 12 of 13 (92%) reacted with Wb-Bhp-1 by immunoblot. The scientists tested 224 sera from individuals with W. bancrofti microfilaremia collected in Sri Lanka, India, Papua New Guinea, Egypt and Côte d’Ivoire. They found that 124/ 224 (55%) sera had anti-Wb-Bhp-1 IgG4 ELISA titers above the threshold of 0.2 OD490, using a BioTek ELx808 plate reader (Agilent Technologies, Santa Clara, CA, USA).

The authors concluded that Wb-Bhp-1, a W. bancrofti homologue of BmR1, is a promising microfilarial antigen for diagnosis of bancroftian filariasis. Specificity testing showed that the Wb-Bhp-1 ELISA had low-level cross-reactivity with samples from people with onchocerciasis or loiasis. Wb-Bhp-1 serology may be especially useful in countries where the combination of ivermectin, diethylcarbamazine (DEC) and albendazole (IDA) can be used to accelerate LF elimination. The study was published on May 23, 2022 in the journal PLOS Neglected Tropical Diseases.

Related Links:
Washington University School of Medicine 
Olympus 
Agilent Technologies


New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Anti-Thyroid Peroxidase Assay
LIAISON Anti-TPO
New
Silver Member
Quality Control Material
NATtrol Chlamydia trachomatis Positive Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.